$183.1 B

MRK Mkt cap, 16-Aug-2018

$20.5 B

Merck Revenue Q2, 2018
Merck Net income (Q2, 2018)2.5 B
Merck Cash, 30-Jun-20185.3 B
Merck EV197.8 B

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 88.3% from Pharmaceutical, 8.7% from Animal Health and 3.0% from Other

Merck Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

44 b42.2 b39.5 b39.8 b40.1 b

Revenue growth, %

(4%)(6%)1%

Cost of goods sold

16 b15.2 b14.4 b13.9 b

Gross profit

28.1 b27.1 b25.1 b25.9 b

Gross profit Margin, %

64%64%63%65%

R&D expense

10.2 b

Operating expense total

10.2 b

Pre tax profit

5.5 b17.3 b5.4 b4.7 b6.5 b

Net Income

4.5 b11.9 b4.5 b3.9 b2.4 b

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

9.3 b9.8 b10.5 b9.4 b9.9 b10 b20.5 b

R&D expense

1.7 b2.2 b1.7 b1.8 b1.7 b3.2 b5.5 b

Operating expense total

1.7 b2.2 b1.7 b1.8 b1.7 b3.2 b5.5 b

Pre tax profit

1.6 b1.5 b2.9 b2 b2.4 b1.3 b3.4 b

Net Income

1.1 b1.2 b2.2 b1.6 b2 b741 m2.5 b

Merck Balance Sheet

Annual

usdY, 2009Y, 2010Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.3 b10.9 b13.5 b13.5 b15.6 b7.4 b8.5 b6.5 b6.1 b

Accounts Receivable

7.2 b6.6 b6.5 b7 b6.9 b

Inventories

6.2 b5.6 b4.7 b4.9 b5.1 b

Current Assets

35.7 b33.2 b29.8 b30.6 b24.8 b

PP&E

12 b12.4 b

Goodwill

12.3 b13 b17.7 b18.2 b18.3 b

Total Assets

105.6 b98.3 b101.8 b95.4 b87.9 b

Accounts Payable

2.3 b2.6 b2.5 b2.8 b3.1 b

Dividends Payable

1.3 b1.3 b1.3 b1.3 b1.3 b

Short-term debt

Current Liabilities

17.9 b18.8 b19.2 b17.2 b18.6 b

Long-term debt

20.5 b18.7 b23.9 b24.3 b21.4 b

Total Debt

20.5 b18.7 b23.9 b24.3 b21.4 b

Retained Earnings

39.3 b46 b45.3 b44.1 b41.4 b

Total Equity

52.3 b48.8 b44.8 b40.3 b34.6 b

Debt to Equity Ratio

0.4 x0.4 x0.5 x0.6 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.3 x

Financial Leverage

2 x2 x2.3 x2.4 x2.5 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

14.1 b15.8 b9.7 b11.4 b8 b6.9 b7.5 b9.7 b6.6 b7.9 b11.7 b7.8 b4.5 b5.3 b

Accounts Receivable

7.6 b7.2 b7 b6.5 b6.7 b6.5 b6.4 b6.9 b6.9 b7.4 b7.1 b7.4 b7.2 b7.3 b

Inventories

6.7 b6.4 b6.1 b5.8 b5.5 b5.3 b5.1 b5.1 b5.2 b5.2 b5.1 b5.4 b5.4 b5.2 b

Current Assets

37.8 b41.2 b33.6 b34.7 b32.9 b28.3 b28.6 b28.8 b27.9 b29.4 b31.5 b28.2 b24.1 b24.1 b

Goodwill

12.1 b12.1 b11.8 b13.2 b17.7 b17.7 b17.8 b17.8 b17.8 b18.3 b18.4 b18.4 b18.3 b18.3 b

Total Assets

106 b108 b97.9 b102 b108 b103 b101 b98.8 b96.5 b98.3 b96.6 b92.8 b86 b85 b

Accounts Payable

2.5 b2.4 b2.3 b2.3 b2.1 b2.3 b2 b2.2 b2.5 b2.5 b2.5 b2.9 b3.2 b3 b

Dividends Payable

1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b1.3 b

Current Liabilities

18.2 b22.5 b17.9 b25.9 b20.4 b17.5 b17.6 b17.6 b14.9 b15.6 b19.8 b18.8 b17 b18.1 b

Long-term debt

22.6 b19.6 b18.6 b18.6 b25.5 b24.1 b24.1 b23.7 b23.6 b23.7 b23.4 b21.7 b21.5 b20 b

Total Debt

22.6 b19.6 b18.6 b18.6 b25.5 b24.1 b24.1 b23.7 b23.6 b23.7 b23.4 b21.7 b21.5 b20 b

Retained Earnings

39.8 b39.7 b40.4 b40 b45.7 b45.1 b45.7 b45.2 b45.1 b46 b44.4 b45 b41.1 b41.5 b

Total Equity

50 b52.6 b48.5 b45.4 b47.9 b46.6 b45.7 b43.9 b43.4 b44 b40.1 b39.7 b33.9 b32.8 b

Financial Leverage

2.1 x2.1 x2 x2.2 x2.3 x2.2 x2.2 x2.2 x2.2 x2.2 x2.4 x2.3 x2.5 x2.6 x

Merck Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

4.5 b11.9 b4.5 b3.9 b2.4 b

Depreciation and Amortization

4.6 b

Accounts Receivable

436 m(554 m)(480 m)(619 m)297 m

Inventories

(365 m)79 m805 m206 m(145 m)

Accounts Payable

522 m593 m(37 m)278 m254 m

Cash From Operating Activities

11.7 b7.9 b12.4 b10.4 b6.4 b

Cash From Investing Activities

(3.1 b)(374 m)(4.8 b)(3.2 b)2.7 b

Short-term Borrowings

(159 m)(460 m)(1.5 b)(26 m)

Cash From Financing Activities

(6 b)(15.1 b)(5.3 b)(9 b)(10 b)

Free Cash Flow

13.2 b9.2 b13.7 b12 b4.6 b

Quarterly

USDQ1, 2018Q2, 2018

Net Income

741 m2.5 b

Depreciation and Amortization

1.1 b2.4 b

Cash From Operating Activities

1.2 b4.5 b

Cash From Investing Activities

(197 m)476 m

Short-term Borrowings

(1 m)2.1 b

Cash From Financing Activities

(2.7 b)(5.7 b)

Free Cash Flow

705 m3.5 b

Merck Ratios

USDY, 2018

EV/CFO

43.6 x

EV/FCF

56.4 x

Financial Leverage

2.6 x
Report incorrect company information

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018

Drugs Approved by FDA

1

Phase III Trials Products

24 20

Products

30

Projects in R&D Pipeline

41 10
Report incorrect company information